Stryker Bets On IVL With AVS Acquisition As CEO Eyes Cardiology Platform Play
Stryker is not building a peripheral vascular business. It is buying one, deal by deal. The April 13 agreement to acquire Amplitude Vascular Systems is its second move in the space after Inari – and CEO Kevin Lobo made clear on the Q1 call that it will not be the last.
Medtech Insight - May 4, 2026

How Stryker’s Cyberattack Hit Ortho And MedSurg Differently – And Recovery Timelines For Each
Forty thousand laptops wiped. Manufacturing shut down. EPS down 8.5%. Yet Stryker walked out of its Q1 earnings call with full-year guidance intact, no identifiable customer losses and a CEO who said the company's brand emerged from the crisis stronger than it went in.
Medtech Insight - May 4, 2026

From Trials To Takeovers: How Global Streamlining Unleashed Billions Of Dollars In Biosimilar M&A
In the wake of two major deals aimed at staking out territory in the biosimilars market, Generics Bulletin speaks to industry leaders about how the changing regulatory environment has given investors confidence to place big-money bets on biosimilars.
Generics Bulletin - May 4, 2026

Stada And Adalvo Debut Ivermectin Cream In Europe
Stada and Adalvo have claimed the first European generic rival to Soolantra, delivering on a day-one launch ambition. Meanwhile, Adalvo has also struck a dermatology deal with Hangzhou SoliPharma for an undisclosed complex product.
Generics Bulletin - May 4, 2026

Astellas Settles Another Mirabegron Lawsuit, With MSN Pharma
The agreement follows a series of earlier legal settlements over generic versions of overactive bladder drug Myrbetriq in the US market.
Generics Bulletin - May 4, 2026

Pipeline Watch: Seven Approvals And Four Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - May 4, 2026

UCB Bets On T-Cell Engagers With $2.2bn Candid Acquisition
UCB’s proposed acquisition of Candid Therapeutics further signals an expansion of its immunology pipeline into T-cell engager-based approaches.
Scrip - May 4, 2026

China Puts Its Stamp On A Record-Breaking Year For Novel Drug Launches
The highest ever number of new active substance launches in 2025 came after China outstripped the US as the market with the most drug debuts.
Scrip - May 4, 2026

Paul Stoffels’s Playbook For Impactful Innovation, How India Can Step Up
Industry doyen and J&J research veteran Paul Stoffels talks about the core principles behind getting innovation right and developing the best science with highest impact on disease, sharing experiences from his storied career along the way.
Scrip - May 4, 2026

Decoding The Regulatory Genome To Target Increased Clinical Success
Early into her role as CSO of Nucleome, a company peeling back the regulatory genome in search of new drug targets, Rising Leader Michelle Morrow took a breather to talk to In Vivo about the journey so far, and to come.
In Vivo - May 4, 2026

Specific Superiority Claims For Ear Wax Removal Muted, More General Claims Resonate In Review
National Advertising Division reviews eosera’s express and establishment claims for Ear Wax MD challenged by Prestige Consumer Healthcare, marketer of Debrox ear wax removal brand.
HBW Insight - May 4, 2026

Nature’s Truth Front-Of-Package Magnesium Claim ‘Literally True’ But Misleading – NAD Review
“Even a literally true claim may reasonably convey a message that is misleading” NAD attorneys say in a review of Nature’s Truth’s claims for its magnesium glycinate gummies supplement challenged by Pharmavite.
HBW Insight - May 4, 2026